Passage Bio, Inc. is a genetic medicines company focused on the development of transformative therapies to treat rare, monogenic central nervous system (CNS) diseases with a high unmet medical need.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
